SpringWorks

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall…

SpringWorks Therapeutics Inc. (SWTX) achieved full enrollment in its Phase 2 trial evaluating nirogacestat SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced that it has achieved full enrollment in its Phase 2 trial evaluating…

<!-- Name:DistributionId Value:8846994 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8778748 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

<!-- Name:DistributionId Value:8756661 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4573 -->…

STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,…

– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints – – NDA Submission to the U.S. FDA Planned for Second Half of 2022; Application to be…

- SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments - - SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat…

STAMFORD, Conn., Sept. 07, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and…

STAMFORD, Conn., Aug. 19, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer,…